Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This prospective, unicentric, open-labe phase I study is to evaluate the effects of
autologous cytokine-induced killer cell immunotherapy combination with PD-1 inhibitor and
chemotherapy in the first-line treatment of IIIB/IIIC/IV non-small cell lung cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital